Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391466 · ClinicalTrials.gov registry record · Phase 3
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 3 study, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 359
- Enrollment target
NCT03391466 is a Phase 3 study that has completed, run by Kite, A Gilead Company. The registered enrollment target is 359 participants.
The verdict
NCT03391466, a Phase 3 study, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 359 participants
- Enrollment target
Study Summary
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Axicabtagene Ciloleucel
- DRUG Platinum-containing Salvage Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2024-11-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03391466
The ClinicalTrials.gov registry entry for NCT03391466 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03391466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03391466 about?
NCT03391466 is a clinical study titled "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma". The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT03391466?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2018-01-25. Estimated completion is 2024-11-25.
What interventions are being tested in trial NCT03391466?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL), Platinum-containing Salvage Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03391466?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.